The transiency of the boost in cytokine levels in both the spleen and tongue tissue is consistent with demonstrations of acquired resistance to PD-1 antibody treatment in melanoma patients and in a mouse lung cancer model [10,11]. The gene discussed is PDCD1; the disease is melanoma.